Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Time to Sell?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) gapped down before the market opened on Wednesday . The stock had previously closed at $25.44, but opened at $24.21. Hemab Therapeutics shares last traded at $25.03, with a volume of 50,300 shares traded.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th.

Hemab Therapeutics Price Performance

Insider Buying and Selling at Hemab Therapeutics

In other news, major shareholder Ra Capital Management, L.P. purchased 6,387 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were acquired at an average price of $24.90 per share, for a total transaction of $159,036.30. Following the acquisition, the insider directly owned 6,372,170 shares in the company, valued at approximately $158,667,033. The trade was a 0.10% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders purchased 2,898,074 shares of company stock valued at $53,650,008.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.